OncoMatch/Blood Cancer — Myelodysplastic (MDS)/TP53
Blood Cancer — Myelodysplastic (MDS)TP53 Clinical Trials
TP53 mutations occur in approximately 10% of MDS and define very high-risk disease with poor prognosis and minimal response to standard hypomethylating agents. Multiple investigational approaches — including p53-reactivating agents (eprenetapopt) and decitabine-based regimens — have been studied without achieving regulatory approval. Trials investigate novel targeted combinations and allogeneic transplant optimization strategies for this high-unmet-need TP53-mutant population.
Top recruiting TP53 Blood Cancer — Myelodysplastic (MDS) trials
Ranked by phase and US site count. See all 13 trials matched to your profile →
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
M.D. Anderson Cancer Center
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Merck Sharp & Dohme LLC
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Sellas Life Sciences Group
Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
M.D. Anderson Cancer Center
Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant
University of Alabama at Birmingham
Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen
St. Petersburg State Pavlov Medical University